202522-22-3 Usage
Description
4-Fluoro-2-(trifluoromethyl)benzylamine is an organic compound characterized by its colorless liquid state. It is a derivative of benzylamine with a fluoro and trifluoromethyl group substitution, which may contribute to its unique chemical properties and potential applications.
Uses
Used in Pharmaceutical Industry:
4-Fluoro-2-(trifluoromethyl)benzylamine is used as a chemical intermediate for the preparation of heterocycle-substituted amide derivatives. These derivatives serve as ACAT (Acyl-CoA: Cholesterol Acyltransferase) inhibitors, which are crucial components in pharmaceutical compositions. ACAT inhibitors are significant in the treatment of various conditions related to cholesterol metabolism and transport, such as atherosclerosis and other cardiovascular diseases. The compound's specific structural features make it a valuable asset in the development of novel therapeutic agents.
Check Digit Verification of cas no
The CAS Registry Mumber 202522-22-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,0,2,5,2 and 2 respectively; the second part has 2 digits, 2 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 202522-22:
(8*2)+(7*0)+(6*2)+(5*5)+(4*2)+(3*2)+(2*2)+(1*2)=73
73 % 10 = 3
So 202522-22-3 is a valid CAS Registry Number.
InChI:InChI=1/C8H7F4N/c9-6-2-1-5(4-13)7(3-6)8(10,11)12/h1-3H,4,13H2/p+1
202522-22-3Relevant articles and documents
TRIAZOLONE COMPOUNDS AS mPGES-1 INHIBITORS
-
Page/Page column 72, (2014/01/08)
The present disclosure is directed to compounds of formula (I), and pharmaceutically acceptable salts thereof, as mPGES-1 inhibitors. These compounds are inhibitors of the microsomal prostaglandin E synthase-1 (mPGES-1) enzyme and are therefore useful in the treatment of pain and/or inflammation from a variety of diseases or conditions, such as asthma, osteoarthritis, rheumatoid arthritis, acute or chronic pain and neurodegenerative diseases.
